Please assess the completion status of the following clinical trial:

Trial Title: Genetic Response to Warfarin in Healthy Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult (\> 18 years old.) subjects not taking warfarin~* Willing and able to grant written informed consent~* Available in proximity to the Medical Center for the anticipated duration of data collection (approximately 3 weeks).~* Pre-menopausal women required negative pregnancy test at study onset and willingness to abstain from sexual activity or use barrier contraception; oral contraceptives interfere with coumadin.~Exclusion Criteria:~* Daily prescribed medications including (1) a medication known to interact with warfarin, based on interactions listed in Micromedex as moderate or severe, and probable or definite (as of study start date, Appendix A) (2) aspirin or clopidogrel, which may increase bleeding risk in combination with warfarin.~* Recent therapy (within two weeks) with a medication known to interact with warfarin based on medication interactions listed in Micromedex~* History of thrombotic disorder requiring anticoagulant therapy~* Thrombophilia or coagulopathy, by history or screening coagulation profile with INR or PTT level \> 2x the upper limit of normal~* Family history of thrombophilia or coagulopathy; prisoners or wards of the state; scheduled elective surgery within one month~* Active liver disease based on clinical history or serum transaminase levels \> 2x the upper limit of normal~* Protein C or S Deficiency assessed on screening protein C and S activity profile~* Age ≥ 75~* Pre-menopausal women on oral contraception~* Non-English speaking individuals

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Warfarin (Type: EXPERIMENTAL): Healthy subjects age 18-74 with no medical indication for warfarin therapy, who are free of medications and co-morbid medical conditions with the potential to interfere with warfarin metabolism, and who are willing to follow a fixed vitamin K diet (men 120 micrograms/day, women 90 micrograms/day) are included.

Based on this trial design, predict the completion outcome and termination type (if applicable).